The global response to the coronavirus disease 2019 (COVID-19) pandemic, driven by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitated unprecedented scientific innovation, culminating in the rapid development and deployment of vaccines. Among these, mRNA-based vaccines, notably BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna/National Institute of Allergy and Infectious Diseases), emerged as pivotal tools, demonstrating remarkable … Leggi tutto Long-Term Safety of mRNA Vaccines: Persistent Spike Protein Expression in Cerebral Arteries and Implications for Hemorrhagic Stroke Risk in a Post-COVID-19 Era